BTSG vs HALO: fair value comparison
BrightSpring Health Services, Inc. and Halozyme Therapeutics, Inc. · Updated 2026-10-19
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, HALO currently sits closer to the top of our ranking by discount to fair value. HALO carries the stronger quality grade.
| BTSG | HALO | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $60.87 | $121.84 |
| 12-month range | $31.36–$72.91 | $61.63–$121.84 |
| Rank by discount to fair value | #35 of 108 Healthcare | #32 of 108 Healthcare |
| Quality grade | D | A |
| Leverage | Moderate | High |
| Margin trend | Stable | Contracting |
| Revenue growth | Strong | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Uptrend |
| DCF cross-check | — | Overvalued |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: BTSG fair value analysis · HALO fair value analysis